[December 02, 2013] |
|
MiniVax, Winner of New Orleans BioInnovation Center's Second Annual BioChallenge Competition
NEW ORLEANS --(Business Wire)--
MiniVax, Inc. (MiniVax) participated in the New Orleans BioInnovation
Center's (NOBIC) second annual BioChallenge, a business competition part
of the three-day Innovation Louisiana 2013 conference. MiniVax and three
other companies were selected out of 19 companies to pitch at the event.
The four companies presented their business plans to a panel of judges
comprised of industry and investment experts. William Heim, Director of
Operations, presented the scientific background, development plans, and
business case for MiniVa. After the pitches were complete, MiniVax was
declared winner and received the prize of $20,000 consisting of cash,
legal services, donated office space, and consulting services.
Martin Preuveneers and Sue Preston, Co-Presidents of MiniVax, said, "We
are delighted to have won this competition, which we feel is an
endorsement of the work and plans we have put in place for MiniVax's
lead program, a monoclonal antibody therapeutic against the fungal lung
infection Pneumocystis pneumonia (PCP)."
About MiniVax
MiniVax is a New Orleans, LA based company that specializes in the
research and development of novel treatments for opportunistic
infections. MiniVax's lead product is a monoclonal antibody therapeutic
against the fungal infection Pneumocystis pneumonia (PCP). PCP
predominately affects immunocompromised patients, such as those
suffering from HIV/AIDS, receiving organ transplants, and undergoing
chemotherapy.
[ Back To TMCnet.com's Homepage ]
|